Three antibiotics, three different AMR battles: why Innoviva’s Prix Galien triple could matter beyond the awards
Innoviva’s XACDURO, ZEVTERA and NUZOLVENCE reach the 2026 Prix Galien finals, spotlighting a growing anti-infective portfolio.
Pharma & Biotech
Pharma & Biotech
How Innoviva’s NUZOLVENCE could reshape STI care and resistance strategy
Innoviva Specialty Therapeutics has received approval from the U.S. Food and Drug Administration for NUZOLVENCE (zoliflodacin), a first-in-class, single-dose oral antibiotic for the treatment of uncomplicated urogenital gonorrhea in adults and adolescents. This approval, based on the largest-ever Phase 3 clinical trial for a new treatment against Neisseria gonorrhoeae, marks the first new oral gonorrhea